Michigan State University Internal Medicine

Topics

• Hepatocellular Carcinoma Treatment and Prognosis 113
• Adrenal and Paraganglionic Tumors 106
• Multiple Myeloma Research and Treatments 106
• Gastrointestinal motility and disorders 78
• CAR-T cell therapy research 77
• Cardiac Valve Diseases and Treatments 75
• Pituitary Gland Disorders and Treatments 62
• Atrial Fibrillation Management and Outcomes 50
• Hormonal Regulation and Hypertension 50
• Hepatitis C virus research 33
• Cancer survivorship and care 28
• HIV/AIDS drug development and treatment 27

Most cited

1. Updated efficacy and safety data from IMbrave150: Atezolizumab plus bevacizumab vs. sorafenib for unresectable hepatocellular carcinoma.

   Journal of hepatology · 2022 · 1,506 citations · Ahmed Kaseb

2. Primary Aldosteronism: An Endocrine Society Clinical Practice Guideline.

   The Journal of clinical endocrinology and metabolism · 2025 · 254 citations · William Young

3. Neoadjuvant-Adjuvant or Adjuvant-Only Pembrolizumab in Advanced Melanoma.

   The New England journal of medicine · 2023 · 739 citations · Kathleen Yost

4. Camrelizumab plus rivoceranib versus sorafenib as first-line therapy for unresectable hepatocellular carcinoma (CARES-310): a randomised, open-label, international phase 3 study.

   Lancet (London, England) · 2023 · 662 citations · Ahmed Kaseb

5. NASH limits anti-tumour surveillance in immunotherapy-treated HCC.

   Nature · 2021 · 1,101 citations · Ahmed Kaseb

6. Atezolizumab plus bevacizumab versus active surveillance in patients with resected or ablated high-risk hepatocellular carcinoma (IMbrave050): a randomised, open-label, multicentre, phase 3 trial.

   Lancet (London, England) · 2023 · 469 citations · Ahmed Kaseb